Unknown

Dataset Information

0

Putative BRAF activating fusion in a medullary thyroid cancer.


ABSTRACT: Medullary thyroid cancer (MTC) is a malignancy of the calcitonin-producing parafollicular cells of the thyroid gland. Surgery is the only curative treatment for this cancer. External beam radiation therapy is reserved for adjuvant treatment of MTC with aggressive features. Targeted therapeutics vandetanib and cabozantinib are approved for the treatment of aggressive and metastatic tumors that are not amenable to surgery. The use of these multikinase inhibitors are supported by the observed overactivation of the RET oncoprotein in a large subpopulation of MTCs. However, not all patients carry oncogenic alterations of this kinase. Hence, there is still a need for comprehensive molecular characterization of MTC utilizing whole-genome and transcriptome-sequencing methodologies with the aim of identifying targetable mutations. Here, we describe the genomic profiles of two medullary thyroid cancers and report the presence of a putative oncogenic BRAF fusion in one. Such alterations, previously observed in other malignancies and known targets of available drugs, can benefit patients who currently have no treatment options.

SUBMITTER: Kasaian K 

PROVIDER: S-EPMC4849853 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Putative BRAF activating fusion in a medullary thyroid cancer.

Kasaian Katayoon K   Wiseman Sam M SM   Walker Blair A BA   Schein Jacqueline E JE   Hirst Martin M   Moore Richard A RA   Mungall Andrew J AJ   Marra Marco A MA   Jones Steven J M SJ  

Cold Spring Harbor molecular case studies 20160301 2


Medullary thyroid cancer (MTC) is a malignancy of the calcitonin-producing parafollicular cells of the thyroid gland. Surgery is the only curative treatment for this cancer. External beam radiation therapy is reserved for adjuvant treatment of MTC with aggressive features. Targeted therapeutics vandetanib and cabozantinib are approved for the treatment of aggressive and metastatic tumors that are not amenable to surgery. The use of these multikinase inhibitors are supported by the observed overa  ...[more]

Similar Datasets

| S-EPMC4546689 | biostudies-literature
| S-EPMC4164813 | biostudies-literature
| S-EPMC10656709 | biostudies-literature
| S-EPMC2360215 | biostudies-other
| S-EPMC3821456 | biostudies-literature
| S-EPMC5889499 | biostudies-literature
| S-EPMC7869888 | biostudies-literature
| S-EPMC6021325 | biostudies-literature
| S-EPMC539203 | biostudies-literature
| S-EPMC5994666 | biostudies-literature